Genentech offers a full range of programs and services to meet the needs of eligible patients and health care professionals. We might be able to help patients with their access needs, from benefits investigations through patient assistance options for those who are eligible.
We have options to help eligible patients pay out-of-pocket costs. Select a product to learn more.
ACTEMRA Copay Card 
RITUXAN EXPERIENCE ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections.
If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and dealth have occured.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions.
Other potential risks of ACTEMRA include demyelinating disorders, malignancies and changes to certain lab parameters.
Common adverse reactions in RA studies included upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Common adverse reactions in SJIA studies included upper respiratory tract infection, headache, nasopharyngitis and diarrhea.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see full Prescribing Information, including Boxed Warning for additional important safety information.
Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Rituxan is not recommended for treatment of patients with severe active infections.
Rituxan has been associated with fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions and progressive multifocal leukoencephalopathy (PML).
Other serious, potentially fatal adverse reactions include hepatitis B reactivation, other infections including bacterial, fungal, new or
reactivated viral infections and cardiovascular events.
Common adverse reactions include infusion reactions and infections.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional safety information, please see the full prescribing information and Medication Guide.